Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

US10577417B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Gregory Beatty · Philadelphia, US
• Boris Engels · Arlington, US
• Neeraja Idamakanti · Burlington, US
• Carl H. June · Yeadon, US
• Andreas Loew · Somerville, US
• Michael C. Milone · Cherry Hill, US
• Huijuan Song · Shanghai, CN
• Enxiu Wang · Upper Darby, US
• Qilong Wu · Shanghai, CN

Key dates

• Filing date: Sep 17, 2015
• Grant date: Mar 3, 2020
• Expiry date: Sep 17, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).